General description
A cell permeable antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC50 = 8 µM) and cyclooxygenase (IC50 = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC50 = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an
IC50 of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).
A cell-permeable and irreversible antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC50 = 8 µM) and cyclooxygenase (IC50 = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC50 = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an IC50 of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
5-lipoxygenase
Product does not compete with ATP.
Reversible: no
Target IC50: 8 µM, 52 µM, against 5-lipoxygenase, Cyclooxygenase, respectively; 6 µM inhibiting the induction of nitric oxide synthase in activated macrophages
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Hung, S., et al. 2008. Mol. Pharmacol.74, 274.
Cui, L., et al. 2007. Antimicrob. Agents Chemother.51, 488.
Salvioli, S., et al. 2007. eCAM4, 181.
Balasubramanyam, K. et al. 2004. J. Biol. Chem.279, 51163.
Brouet, I., and Okshima, H. 1995. Biochem. Biophys. Res. Commun. 206, 533.
Korutla, L., and Kumar, R. 1994. Biochim. Biophys. Acta1224, 597.
Flynn, D.L., et al. 1986. Prostagland. Leuk. Med. 22, 357.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
| Quality Level | 100 |
| description | Merck USA index - 14, 2673 |
| assay | ≥80% (HPLC) |
| form | solid |
| manufacturer/tradename | Calbiochem® |
| storage condition | OK to freeze,protect from light |
| color | orange-yellow |
| solubility | acetic acid: 10 mg/mL,DMSO: 5 mg/mL |
| shipped in | ambient |
| storage temp. | 10-30°C |
| InChI | 1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13- |
| InChI key | ZIUSSTSXXLLKKK-KOBPDPAPSA-N |
